Trial · NCT00622726
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
NCT00622726, Phase 2, Unknown, The University of Texas Health Science Center, Houston; results first posted 2014-06-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity. Trials, record NCT00622726. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00622726
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
- NCT number
- NCT00622726
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 150 participants, actual
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Conditions
- Retinopathy of Prematurity
- Interventions
- Bevacizumab, Conventional Laser for ROP
- First posted
- 2008-02-25
- Last updated
- 2017-06-06
- Results first posted
- 2014-06-09
- Limitations and caveats
- Limitations:~1. number of patients is too small to determine efficacy of bevacizumab in posterior zone II ROP.~2. number of patients is too small to determine safety of bevacizumab systemically.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Eyes Showing Recurrence of Neovascularization Arising From the Retinal Vessels and Requiring Re-treatment | 54 weeks postmenstrual age (window of 50 to 70 weeks) | For Bevacizumab: Regrowth of new vessels at the site of the original extraretinal fibrovascular proliferation and/or at the site of the anterior edge of inner retinal vascularization. For Laser: Regrowth of new vessels from the vessels at the anterior edge of inner retinal vascularization (remaining after retinal ablation). |
| Secondary | Myopia in Zone I and Posterior Zone II of Infant Eyes | 2.5 years of age | Myopia was determined via refraction using a retinoscope and lenses. Myopia is defined as a refractive error reported in Diopters. |
| Secondary | Visual Acuity | Age 7 years. | The visual acuity will be measured at 20 feet with figures or letters from all infants able to cooperate. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Eyes Showing Recurrence of Neovascularization Arising From the Retinal Vessels and Requiring Re-treatment | 54 weeks postmenstrual age (window of 50 to 70 weeks) | Both eyes of all surviving infants were analyzed for recurrence: thus, 143 surviving infants and 286 eyes were analyzed. Reporting the number of eyes that developed recurrences | eyes with recurrences | NUMBER |
| SECONDARY | Myopia in Zone I and Posterior Zone II of Infant Eyes | 2.5 years of age | As of 6/2013, there were 13 deaths/ 26 eyes. Exclusions from surviving 137 infants/ 274 eyes: 6 infants/19 eyes with intraocular surgery--leaving: 131 infants/ 255 eyes; 14 infants/ 21 eyes had recurrence and 22 infants/ 44 eyes were lost to follow-up--leaving: 95 infants/ 190 eyes. Thus, only the refractions on these infants/ eyes are given. | Diopters | MEAN |
| SECONDARY | Visual Acuity | Age 7 years. |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Eyes Showing Recurrence of Neovascularization Arising From the Retinal Vessels and Requiring Re-treatment | Bevacizumab for ROP-Experimental Arm | 6 | eyes with recurrences | ||
| Number of Eyes Showing Recurrence of Neovascularization Arising From the Retinal Vessels and Requiring Re-treatment | Conventional Laser for ROP-Control Arm | 32 | eyes with recurrences | ||
| Myopia in Zone I and Posterior Zone II of Infant Eyes | Bevacizumab-Experimental Group: Zone I | -1.36 | Standard Deviation 3.34 | Diopters | |
| Myopia in Zone I and Posterior Zone II of Infant Eyes | Conventional Laser-Control Group: Zone I | -7.34 | Standard Deviation 7.44 | Diopters | |
| Myopia in Zone I and Posterior Zone II of Infant Eyes | Bevacizumab Experimental Group: Posterior Zone II | -0.63 | Standard Deviation 2.56 | Diopters | |
| Myopia in Zone I and Posterior Zone II of Infant Eyes | Conventional Laser-Control Group: Posterior Zone II | -5.20 | Standard Deviation 5.77 | Diopters |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| March, 2008 to August, 2010 | STARTED | Bevacizumab for ROP-Experimental Arm | 75 | |
| March, 2008 to August, 2010 | STARTED | Conventional Laser for ROP-Control Arm | 75 | |
| March, 2008 to August, 2010 | COMPLETED | Bevacizumab for ROP-Experimental Arm | 70 | |
| March, 2008 to August, 2010 | COMPLETED | Conventional Laser for ROP-Control Arm | 73 | |
| March, 2008 to August, 2010 | NOT COMPLETED | Bevacizumab for ROP-Experimental Arm | 5 | |
| March, 2008 to August, 2010 | NOT COMPLETED | Conventional Laser for ROP-Control Arm | 2 | |
| August, 2010 to April, 2013 | STARTED | Bevacizumab for ROP-Experimental Arm | 70 | |
| August, 2010 to April, 2013 | STARTED | Conventional Laser for ROP-Control Arm | 73 | |
| August, 2010 to April, 2013 | COMPLETED | Bevacizumab for ROP-Experimental Arm | 69 | |
| August, 2010 to April, 2013 | COMPLETED | Conventional Laser for ROP-Control Arm | 68 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bevacizumab for ROP-Experimental Arm | ||
| Total, all-cause mortality | Conventional Laser for ROP-Control Arm | ||
| Total, other adverse events | Bevacizumab for ROP-Experimental Arm | 0 | 69 |
| Total, other adverse events | Conventional Laser for ROP-Control Arm | 0 | 68 |
| Total, serious adverse events | Bevacizumab for ROP-Experimental Arm | 0 | 69 |
| Total, serious adverse events | Conventional Laser for ROP-Control Arm | 0 | 68 |
Source ClinicalTrials.gov
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Bevacizumab for ROP-Experimental Arm vs Conventional Laser for ROP-Control Arm: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00622726
GET https://conductscience.org/api/trials/v1/NCT00622726/registered